GLP1_NEW
ECC5004 5 mg tablet once daily
ECC500_PO_5MG_QD
Effects across outcomes
Bayesian random effects estimate against the comparator of each analysis (usually placebo), posterior median and 95% credible interval. Green: clearly better; red: clearly worse.
| Condition | Outcome | Window | Versus | Effect (95% CrI) | SUCRA |
|---|---|---|---|---|---|
| Type 2 diabetes (adults) | Serious adverse events | longest follow-up | Placebo | HR 0.76 (0.01 to 56.32) | 0.53 |
| Type 2 diabetes (adults) | Nausea | longest follow-up | Placebo | HR 0.84 (0.06 to 7.52) | 0.73 |
| Type 2 diabetes (adults) | Vomiting | longest follow-up | Placebo | HR 0.39 (0.01 to 11.97) | 0.79 |
| Type 2 diabetes (adults) | Diarrhea | longest follow-up | Placebo | HR 1.71 (0.30 to 8.59) | 0.47 |
| Type 2 diabetes (adults) | Constipation | longest follow-up | Placebo | HR 0.10 (0.00 to 1.28) | 0.92 |